Latest News

Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillo-facial Procedures

New research presented at AAOMS 2016 shows EXPAREL is safe and effective for pain relief following removal of wisdom teeth

PARSIPPANY, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that provides prolonged non-opioid postsurgical pain control.

Nicht definiert

US FDA grants orphan drug status to TLC178 to treat cutaneous T-cell lymphoma

Taipei City Friday, October 21, 2016, Taiwan Liposome Company (TLC) announced that product candidate TLC178 has been granted an orphan drug designation for the treatment of cutaneous T-cell lymphoma (CTCL) by the US Food and Drug Administration (FDA). Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL). T-cell lymphomas account for approximately 15 percent of all cases of NHL in the US, with cutaneous T-cell lymphoma being one of the most common forms of T-cell lymphoma.